Entia Biosciences Inc (ERGO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2010 | 06-2010 | 03-2010 | 12-2009 | 09-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -922 | -493 | -302 | -920 | -424 |
| Depreciation Amortization | 171 | 106 | 41 | 2 | 1 |
| Accounts receivable | -65 | -43 | 0 | -3 | -31 |
| Other Working Capital | 102 | -13 | -39 | 160 | -24 |
| Other Operating Activity | 310 | 69 | 13 | 211 | 10 |
| Operating Cash Flow | $-405 | $-374 | $-286 | $-550 | $-469 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -30 | -18 | -11 | -20 | -4 |
| Net Acquisitions | N/A | N/A | N/A | -30 | N/A |
| Purchase Sale Intangibles | -34 | -26 | -17 | -36 | N/A |
| Other Investing Activity | -90 | -84 | -28 | -160 | -159 |
| Investing Cash Flow | $-120 | $-102 | $-40 | $-210 | $-163 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 100 | 100 | 100 | 50 | N/A |
| Debt Issued | 455 | 450 | 450 | 17 | N/A |
| Common Stock Issued | N/A | N/A | N/A | 530 | 565 |
| Other Financing Activity | -18 | -13 | -6 | -57 | -17 |
| Financing Cash Flow | $537 | $538 | $544 | $540 | $549 |
| Beginning Cash Position | 48 | 48 | 48 | 270 | 273 |
| End Cash Position | 61 | 110 | 266 | 40 | 190 |
| Net Cash Flow | $13 | $62 | $218 | $-220 | $-83 |
| Free Cash Flow | |||||
| Operating Cash Flow | -405 | -374 | -286 | -550 | -469 |
| Capital Expenditure | -30 | -18 | -11 | -21 | -4 |
| Free Cash Flow | -435 | -392 | -297 | -571 | -473 |